Defence Therapeutics

Defence Therapeutics is a publicly traded company specializing in precision intracellular drug delivery, focusing on enhancing the efficacy of cancer biologics through its proprietary Accum platform. The company aims to improve the potency and safety of antibody-drug conjugates (ADCs), radiopharmaceuticals, and other advanced therapies, making them... more effective first-line treatments. With a strong intellectual property portfolio and a pipeline that includes partnerships for licensing and co-development, Defence Therapeutics is positioned to capitalize on the growing oncology market. Their vision is to ensure that every cancer therapy achieves its full potential, ultimately transforming patient outcomes worldwide.Read More